BioCentury
ARTICLE | Company News

Biotie, Pfizer deal

October 25, 2010 7:00 AM UTC

Biotie will regain rights to undisclosed preclinical compounds related to phosphodiesterase-10 (PDE-10) inhibitors to treat CNS disorders, including schizophrenia, after the parties mutually terminat...